NRx Pharmaceuticals, Inc. (NRXP) Financial Ratios
9 years of historical data (2017–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
N/A
—
5yr avg: 103.16
30Y Low1.3·High107.8
ROE
↑
N/A
—
5yr avg: -364.5%
30Y Low-447%·High1%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low4.0·High8.4
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
NRXP Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
NRx Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $69M | $58M | $23M | $35M | $730M | $2.2B | $133M | $54M | $91M | $87M |
| Enterprise Value | $61M | $51M | $28M | $39M | $720M | $2.2B | $132M | $56M | $92M | $87M |
| P/E Ratio → | -2.96 | — | — | — | — | — | — | 132.50 | 1376.52 | — |
| P/S Ratio | 56.02 | 47.35 | — | — | — | — | — | — | — | — |
| P/B Ratio | — | — | — | — | 98.53 | 107.79 | — | 1.83 | 1.31 | 1.26 |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
NRXP EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 41.50 | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | 113.45 | 1112.87 | — |
| EV / EBIT | — | — | — | — | — | — | — | 113.45 | 1112.87 | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
NRXP Profitability
Margins and return-on-capital ratios measuring operating efficiency
NRx Pharmaceuticals, Inc. earns an operating margin of -1324.4%.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 58.8% | 58.8% | — | — | — | — | — | — | — | — |
| Operating Margin | -1324.4% | -1324.4% | — | — | — | — | — | — | — | — |
| Net Profit Margin | -2336.5% | -2336.5% | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | -281.8% | -447.3% | — | 0.8% | 0.1% | -0.2% |
| ROA | -344.7% | -344.7% | -458.3% | -182.0% | -135.8% | -521.8% | -295.7% | 0.8% | 0.1% | -0.2% |
| ROIC | — | — | — | — | — | — | — | -1.1% | -1.1% | — |
| ROCE | — | — | — | — | -285.7% | -457.6% | — | -1.4% | -1.4% | — |
NRXP Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $8M exceeds total debt of $631000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 1.42 | 0.02 | — | 0.07 | 0.01 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | 3.96 | 8.37 | — |
| Net Debt / Equity | — | — | — | — | -1.29 | -1.30 | — | 0.07 | 0.01 | -0.01 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | 3.96 | 8.24 | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -41.66 | -41.66 | -22.29 | -250.25 | — | -5169.17 | -923.59 | — | — | — |
Net cash position: cash ($8M) exceeds total debt ($631000)
NRXP Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.31x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 0.36x to 0.31x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.31 | 0.31 | 0.15 | 0.36 | 1.66 | 2.74 | 0.06 | 0.11 | 0.05 | 5.76 |
| Quick Ratio | 0.31 | 0.31 | 0.15 | 0.36 | 1.66 | 2.74 | 0.06 | 0.11 | 0.05 | 5.76 |
| Cash Ratio | 0.27 | 0.27 | 0.07 | 0.24 | 1.29 | 2.32 | 0.04 | 0.00 | 0.02 | 4.82 |
| Asset Turnover | — | 0.09 | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | 0.01 | — | — | — |
| Days Sales Outstanding | — | 47.97 | — | — | — | — | — | — | — | — |
NRXP Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
NRx Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | 0.8% | 0.1% | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 75.5% | 0.0% | 80.1% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 75.5% | 0.0% | 80.1% |
| Shares Outstanding | — | $21M | $11M | $8M | $66M | $47M | $546586 | $508835 | $892496 | $903550 |
Peer Comparison
Compare NRXP with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 NRXPYou | $69M | -3.0 | — | — | 58.8% | -1324.4% | — | — | — |
 AXSM | $13B | -68.1 | — | — | 92.6% | -26.5% | -252.1% | -1906.7% | — |
 ALTO | $388M | 31.4 | 14.0 | 44.9 | 3.8% | 0.8% | 5.7% | 1.9% | 3.0 |
 INMB | $39M | -0.8 | — | — | 100.0% | -61738.0% | -165.2% | -407.4% | — |
 ATAI | $1B | -1.4 | — | — | 75.3% | -2439.7% | -389.9% | -57.0% | — |
 CMPS | $1B | -4.1 | — | — | — | — | -565.3% | — | — |
 MNMD | $2B | -10.0 | — | — | — | — | -64.1% | -389.5% | — |
 NRXS | $89M | -7.5 | — | — | 84.2% | -219.4% | -285.4% | — | — |
 PFE | $143B | 18.5 | 10.3 | 15.8 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
 JNJ | $550B | 39.4 | 19.1 | 27.7 | 69.1% | 24.9% | 20.1% | 20.7% | 1.2 |
 ABBV | $383B | 91.4 | 15.8 | 21.5 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
NRXP — Frequently Asked Questions
Quick answers to the most common questions about buying NRXP stock.
What is NRx Pharmaceuticals, Inc.'s P/E ratio?
NRx Pharmaceuticals, Inc.'s current P/E ratio is -3.0x. The historical average is 132.5x.
Is NRXP stock overvalued?
Based on historical data, NRx Pharmaceuticals, Inc. is trading at a P/E of -3.0x. Compare with industry peers and growth rates for a complete picture.
What are NRx Pharmaceuticals, Inc.'s profit margins?
NRx Pharmaceuticals, Inc. has 58.8% gross margin and -1324.4% operating margin.